Castration-Resistant Prostate Cancer (Trumpet-ONC-MA-1004)

May 09, 2017

Sponsor: Astellas Pharma Global Development, Inc.

Number: Trumpet-ONC-MA-1004

The purpose of this study is to describe patterns of care in CRPC (Castration-Resistant Prostate Cancer) patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.

This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and triggers for treatment, changes for CRPC, as well as describe clinical outcomes based on patient characteristics.

Who’s eligible:

• The patient must have a confirmed diagnosis of CRPC defined by both Testosterone at castrate levels, and Clear progressive disease, as evidenced by a minimum of two rising PSA (a blood test used primarily to screen for prostate cancer) levels measured at least 7 days apart or new clinical or imaging evidence of progressive metastatic disease
• Patients may be enrolled within 90 days from the time of decision to treat or within 90 days of treatment initiation. The patient must be willing and able to complete periodic patient-reported outcome (PRO) questionnaires, with or without assistance.
• Patient must have an estimated life expectancy of ≥ 6 months
• This study is for male patients age 18 and older.

Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.